Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.15), $0.03 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $13.1 million versus the consensus estimate of $11.43 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

Earnings Guidance

Sangamo BioSciences (SGMO) PT Raised to $33 at JefferiesFebruary 23, 2018 8:58 AM Sangamo BioSciences (SGMO) PT Raised to $35 at JPMorganFebruary 23, 2018 7:24 AM Sangamo BioSciences (SGMO) PT Raised to $32 at Piper Jaffray, Remains Positive Citing Broadening PlatformFebruary 22, 2018 4:26 PM Sangamo BioSciences (SGMO) PT Raised to $39 at Wells FargoFebruary 22, 2018 12:23 PM Sangamo BioSciences (SGMO) PT Raised to $30 at BarclaysFebruary 22, 2018 11:56 AM Sangamo Therapeutics Reports Fourth Quarter And Full Year 2017 Financial ResultsFebruary 22, 2018 7:00 AM